Marca Nominativa depositada no INPI em 10/08/2022 por Seqirus UK Limited, processo nº 501701927, nas classes 01, 05, 41, 42, 44. Registro em vigor até 10/08/2032.
| Número do processo | 501701927 |
|---|---|
| Situação | Registro de marca em vigor (Madri) |
| Apresentação | Nominativa |
| Natureza | Madri Produto/Serviço |
| Data do depósito | 10/08/2022 |
| Data da concessão | 22/10/2024 |
| Vigência até | 10/08/2032 |
| Titular | Seqirus UK Limited |
| CNPJ/CPF do titular | — |
| UF · País | — · GB |
Chemical and biological reagents in this class; cell cultures and media in this class; laboratory and scientific test kits in this class; chemical preparations for scientific and/or industrial purposes; diagnostic and testing agents; chemical and biological reagents for non-medical purposes; chemical and biological reagents for industrial use for anti-body screening, blood grouping, and for the typing and detection of specific blood cells, determining the presence of antigens on blood cells, and the detection of relevant complement compounds and immunoglobulin subtypes; chemical test kits for the detection of specific blood cells, determining the presence of antigens on blood cells, and the detection of relevant complement compounds and immunoglobulin subtypes for laboratory or research use; chemical preparations for industrial use for anti-body screening, blood grouping, and the typing and detection of specific blood cells.;
Pharmaceutical preparations and substances in this class; vaccines; blood products; products derived from blood and products derived from recombinant DNA technology; serums; antibodies; medical and veterinary test kits; influenza vaccines; adjuvants and antigens; pharmaceutical preparations and substances for the treatment and/or prevention of blood or bleeding disorders; blood products, namely, blood plasma, reagent blood cells; products derived from blood and products derived from recombinant DNA technology, namely, immunoglobulins, human albumin, blood clotting factors, plasma volume expanders, blood proteins for therapeutic use; serums, namely, anti-venoms; medicated serums for the treatment of blood or bleeding disorders; test kits, namely, invitro diagnostic reagent test kits for use in detecting cell mediated immune response; pharmaceutical preparations and substances, namely, RhD reagents for the detection of specific antigens or in blood typing; pharmaceutical preparations, namely, reagent red blood cells used to detect antibodies or IgG subtypes; pharmaceutical preparations, namely, monoclonal and polyclonal antibodies; pharmaceutical preparations, namely, reagents for medical/clinical use for the typing and detection of specific blood cells, and the detection of relevant compliment components and immunoglobulin subtypes.;
Education services including medical education services; health education; consultancy services relating to education; provision of education services via an online forum; provision of training and education courses; publication of educational materials; dissemination of educational material; weblog (blog) services; electronic publication of information on a wide range of topics, including online and over a global computer network.;
Scientific and technological services; research and development services relating to scientific, medical, pharmaceutical and blood products; industrial analysis; clinical trials; conducting clinical trials; provision of testing facilities; rental of research facilities; laboratory analysis and research; management of scientific research projects; preparation of technical studies, technical reports, scientific reports; management of scientific research projects, preparation of scientific and medical research projects, preparation of statistics or reports relating to scientific and medical research; provision of research services and facilities, provision of research results, information and outcomes; provision of information relating to the aforementioned services; advisory and consultancy services relating to the aforementioned services; dissemination of information relating to the aforementioned services over a global computer network; medical laboratory services, namely, scientific testing and screening services, namely, testing of human blood plasma for safety and quality; medical laboratory services regarding human blood plasma; hosting an Internet-based database where patients can enquire about medical issues and procedures from other patients and can relay information about their medical experiences for support.;
Medical services; medical information services; health care services; health care information services; patient support services; providing medical information concerning blood products; providing medical information concerning vaccines, anti-venoms and immunohaematology products, namely, diagnostic reagents; patient support services, namely, providing patient medical information where patients can enquire about medical issues and procedures from other patients and can relay information about their medical experiences for support and community via an Internet-based database.;
Receba um e-mail a cada novo despacho publicado na RPI para o processo 501701927 — exigência, oposição, deferimento, prazo de pagamento — e quando alguém depositar uma marca parecida.
Monitorar esta marca Ver marcas parecidas7 despacho(s) publicado(s) na Revista da Propriedade Industrial.